TNR Gold Corp (TSX-V:TNR, OTC:TRRXF) revealed that it has successfully closed a July 2022 royalty purchase agreement, with an Ontario limited partnership affiliated with Lithium Royalty Corp (LRC), for the sale of a portion of its net smelter returns (NSR) royalty involving Ganfeng Lithium’s Mariana Lithium project in in the Salta province of Argentina, one of the biggest lithium brine deposits in the world.
The Vancouver-based green energy metals royalty and gold company said LRC has purchased from TNR a 0.5% NSR royalty for US$9 million, including 0.05% NSR royalty sold by TNR on behalf of its shareholder. This represents one-quarter of the NSR royalty held by the company. LRC is an arms' length party to the company.
Nextech AR Solutions Corp. (CSE:NTAR, OTCQX:NEXCF) has announced that after further consideration, it has determined to pursue a direct spinout of its generative AI-powered Toggle3D platform through a wholly-owned subsidiary of the company.
The transaction is currently anticipated to proceed by way of plan of arrangement under which the Toggle3D platform and associated assets will be spun out into a new Subco, but will be subject to final tax and legal structuring considerations.
Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) told investors that it has amended and restated the terms of the balance of a $54 million senior debt facility its subsidiary Segilola Resources Operating Limited (SROL) entered into with Africa Finance Corporation (AFC) close to three years ago for the construction of the Segilola gold mine in Nigeria’s Osun State.
The company noted that Segilola started ramping up production in the fourth quarter of 2021 and achieved full commercial production at the beginning of 2022, with total annual production of 98,008 ounces (oz) of gold in the full year 2022. By 31 December 2022, SROL had repaid or cancelled $25.6 million of the Project Facility, reducing the facility outstanding to $28.4 million.
Toubani Resources Inc. (TSX-V:TRE, ASX:TRE) has updated investors on its activities for the period ending December 31, 2022, during which it successfully listed on the ASX, raising A$6 million.
Other highlights during the period include the appointment of a drilling contractor to undertake a targeted 10,750 metre (m) exploration campaign at Kobada in Mali and the appointment of Phil Russo as chief executive officer and executive director.
Imugene Ltd (ASX:IMU, OTC:IUGNF) has progressed its Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33- hNIS (VAXINIA) to the next stage, clearing cohort 2 of both the intravenous (IV) and intratumoral (IT) arms of the monotherapy trial.
The company’s success has allowed it to open cohort 1 of the combination study (with Pembrolizumab, an immune checkpoint inhibitor antibody) and cohort 3 for both arms of the monotherapy dose escalation portion of the trial.
GR Silver Mining (TSX-V:GRSL) said t it has accepted the resignation of Jonathan Rubenstein from its board of directors. Rubenstein was appointed to the company's board in September 2020 after previously serving on its Advisory Board. GR Silver Mining chairman Eric Zaunscherb commented: "Jonathan has been a valuable contributor to GR Silver's board and we have benefitted greatly from his knowledge and decades of experience. On behalf of the Board of Directors, management and the company's shareholders, I wish Jonathan and his family all the best in the future." The company said its board is actively engaged in identifying and evaluating alternatives with respect to the appointment of a new independent director to fill the vacancy left by Rubenstein's departure. "We are particularly interested in building technical expertise at the board level as the prospective Plomosas Project is advanced," added Zaunscherb. "The recent appointment of Mr Larry Taddei, the former chief financial officer of MAG Silver Corp, as an independent director positions the company well as we go forward."
Xeris Biopharma Holdings (NASDAQ:XERS) has announced that members of its senior management will hold 1x1 investor meetings and present an overview of the company at the SVB Securities Global Biopharma Conference 2023, which is taking place in a virtual format on Wednesday, February 15, 2023, from 10.40am–11.10am ET. An audio webcast of the presentation can be accessed by visiting ‘Upcoming Events’ in the Investors section on the company's website at www.xerispharma.com.
Sidus Space Inc (NASDAQ:SIDU) announced the closing of an underwritten public offering of 17,250,000 shares of its Class A common stock that generated $5.2 million in gross proceeds. The company intends to use the net proceeds of the offering for sales and marketing, operational costs, product development, manufacturing expansion, working capital and other general corporate purposes. The shares of Class A common stock were sold to the public at a price of $0.30 per share, and the offering included the full exercise of the underwriters’ over-allotment option.